MHP
ANIK icon

Manatuck Hill Partners’s Anika Therapeutics ANIK Stock Holding History

Manatuck Hill Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,000
Closed -$362K – 110
2020
Q4 		$362K Buy
+8,000
New +$304K 0.14% 82

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Manatuck Hill Partners's ANIK Position: Q1 2021 in Review

Manatuck Hill Partners sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 8,000 shares — an estimated $362K sold.

Manatuck Hill Partners first reported a position in ANIK in Q4 2020 and held it in 1 quarter. The position peaked at $362K in Q4 2020. 146 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

  • Manatuck Hill Partners reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Manatuck Hill Partners sold 8,000 Anika Therapeutics shares in Q1 2021, an estimated $362K.
  • Manatuck Hill Partners first reported a position in Anika Therapeutics in Q4 2020 and held it in 1 quarter.
  • Manatuck Hill Partners's Anika Therapeutics position peaked at $362K in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on Manatuck Hill Partners's 13F filing for Q1 2021, filed 14 May 2021.